The agenda for the Transparency Council, which will meet on January 31st, is:
Preparation of positions on drug evaluation:
Venclyxto (venetoclaxum) as part of the drug program: "Treatment of patients with acute myeloid leukemia with venetoclax in combination with azacitidine (ICD-10 C92.0)",
Bavencio ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
